الفهرس 
Allogeneic hematopoietic cell transplantationOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Recent clinical studies indicated that administration of cyclophosphamide (Cy) post allogeneic hematopoietic stem cell transplantation (aHSCT) and post-transplant cyclophosphamide (PTCy) can reduce graft versus host disease (GvHD). The mechanisms behind these beneficial effects of PTCy, however, are still obscured. Given that one of the mechanisms mediating decreases of GvHD by Cy is the Granulocytes (CD33+CD11b+) which contain subpopulation of immunosuppressive cells. We aimed in this study to analyze the immunophenotyping of granulocytes (CD33+CD11b+) after PTCy treatment and to correlate it with clinical setting. Children with ³-thalassemia major (Pesaro class II) (n = 5: 2 males and 3 females) were treated with Cy (30 mg/Kg/dose) before HSCs transplantation on days -5, -4, -3 and -2 before transplantation, then the patients were infused with mobilized CD34+ blood (5 million cells/Kg) harvested from allogenic donors pretreated with granulocyte colony stimulating factor (G-CSF) for 5 consecutive days. Recipients were then treated with Cy (40 mg/Kg/dose) on days +3 and +4 after HSCT.